Details of the Drug

General Information of Drug (ID: DMCR1MV)

Drug Name
Itraconazole
Synonyms
Canadiol; Hyphanox; ITCZ; ITZ; Intraconazole; Itraconazol; Itraconazolum; Itrizole; Oriconazole; Orungal; Prokanazol; Sempera; Spherazole; Sporal; Sporanos; Sporanox; Sporonox; Triasporn; Itraconazol [Spanish]; Itraconazole oral solution; Itraconazolum [Latin]; R 51211; Cis-Itraconazole; Itraconazole & Bovine Lactoferrin; Itraconazole & Nyotran; Itrizole (TN); R-51211; Sporanox (TN); Itraconazole & Nyotran(Liposomal Nystatin); Itraconazole (JAN/USAN); Oriconazole, R51211, Sporanox; Itraconazole [USAN:BAN:INN:JAN]; (+-)-1-sec-Butyl-4-(p-(4-(p-(((2R*,4S*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-delta(sup 2)-1,2,4-triazolin-5-one; (1)-cis-4-(4-(4-(4-((2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-2-sec-butyl-3H-1,2,4-triazol-3-one; 2-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[(2S,4R)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 2-butan-2-yl-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; 3H-1,2,4-Triazol-3-one, 4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-pipera-zinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl); 4-(4-{4-[4-({[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl}oxy)phenyl]piperazin-1-yl}phenyl)-2-(1-methylpropyl)-2,4-dihydro-3H-1,2,4-triazol-3-one
Indication
Disease Entry ICD 11 Status REF
Fungal infection 1F29-1F2F Approved [1]
Therapeutic Class
Antifungal Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 3 Molecular Weight (mw) 705.6
Topological Polar Surface Area (xlogp) 5.7
Rotatable Bond Count (rotbonds) 11
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 9
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Bioavailability
The bioavailability of drug is 55% [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 5.1 mL/min/kg [4]
Elimination
0.03% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 21 hours [4]
Metabolism
The drug is metabolized via the liver [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 14.17132 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.002% [4]
Vd
The volume of distribution (Vd) of drug is 796 +/- 185 L [6]
Water Solubility
The ability of drug to dissolve in water is measured as 0.000001 mg/mL [2]
Chemical Identifiers
Formula
C35H38Cl2N8O4
IUPAC Name
2-butan-2-yl-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one
Canonical SMILES
CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl
InChI
InChI=1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25?,31-,35-/m0/s1
InChIKey
VHVPQPYKVGDNFY-ZPGVKDDISA-N
Cross-matching ID
PubChem CID
55283
ChEBI ID
CHEBI:6076
CAS Number
84625-61-6
DrugBank ID
DB01167
TTD ID
D0V4IB
VARIDT ID
DR00687
INTEDE ID
DR0895
ACDINA ID
D00337

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Candida Cytochrome P450 51 (Candi ERG11) TTTSOUD CP51_CANAL Modulator [7]
Hedgehog signaling pathway (HS pathway) TT4LXBC NOUNIPROTAC Inhibitor [8], [9]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [11]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Itraconazole (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sodium bicarbonate DMMU6BJ Moderate Decreased absorption of Itraconazole due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [46]
Clindamycin DM15HL8 Moderate Decreased metabolism of Itraconazole caused by Clindamycin mediated inhibition of CYP450 enzyme. Acne vulgaris [ED80] [47]
Ivosidenib DM8S6T7 Major Decreased metabolism of Itraconazole caused by Ivosidenib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [48]
Midostaurin DMI6E0R Major Decreased metabolism of Itraconazole caused by Midostaurin mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [49]
Idarubicin DMM0XGL Moderate Decreased clearance of Itraconazole due to the transporter inhibition by Idarubicin. Acute myeloid leukaemia [2A60] [50]
Arn-509 DMT81LZ Moderate Increased metabolism of Itraconazole caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [51]
Gilteritinib DMWQ4MZ Major Decreased metabolism of Itraconazole caused by Gilteritinib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [52]
Oliceridine DM6MDCF Major Decreased metabolism of Itraconazole caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [53]
Ivabradine DM0L594 Major Decreased metabolism of Itraconazole caused by Ivabradine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [54]
Dronedarone DMA8FS5 Major Decreased metabolism of Itraconazole caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [54]
Bedaquiline DM3906J Moderate Decreased metabolism of Itraconazole caused by Bedaquiline mediated inhibition of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [55]
Posaconazole DMUL5EW Moderate Decreased metabolism of Itraconazole caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [51]
Budesonide DMJIBAW Major Decreased metabolism of Itraconazole caused by Budesonide mediated inhibition of CYP450 enzyme. Asthma [CA23] [56]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Itraconazole caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [57]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Itraconazole caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [58]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Itraconazole caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [58]
Cariprazine DMJYDVK Major Decreased metabolism of Itraconazole caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [59]
Erdafitinib DMI782S Major Decreased metabolism of Itraconazole caused by Erdafitinib mediated inhibition of CYP450 enzyme. Bladder cancer [2C94] [60]
Pexidartinib DMS2J0Z Major Decreased metabolism of Itraconazole caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [61]
Talazoparib DM1KS78 Major Decreased clearance of Itraconazole due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [51]
Ixabepilone DM2OZ3G Moderate Decreased metabolism of Itraconazole caused by Ixabepilone mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [62]
Lapatinib DM3BH1Y Major Decreased metabolism of Itraconazole caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [54]
HKI-272 DM6QOVN Major Decreased metabolism of Itraconazole caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [63]
LY2835219 DM93VBZ Major Decreased metabolism of Itraconazole caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [64]
Esterified estrogens DM9KZDO Moderate Decreased metabolism of Itraconazole caused by Esterified estrogens mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [65]
Tucatinib DMBESUA Moderate Decreased metabolism of Itraconazole caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [66]
Quinestrol DMJ6H1Z Moderate Decreased metabolism of Itraconazole caused by Quinestrol mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [65]
Cabazitaxel DMPAZHC Moderate Decreased metabolism of Itraconazole caused by Cabazitaxel mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [54]
Bosutinib DMTI8YE Major Decreased metabolism of Itraconazole caused by Bosutinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [54]
Trastuzumab Emtansine DMU1LXS Moderate Decreased metabolism of Itraconazole caused by Trastuzumab Emtansine mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [54]
Macitentan DMP79A1 Major Decreased metabolism of Itraconazole caused by Macitentan mediated inhibition of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [67]
PF-04449913 DMSB068 Major Decreased metabolism of Itraconazole caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [68]
Vilanterol DMF5EK1 Moderate Decreased metabolism of Itraconazole caused by Vilanterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [69]
Indacaterol DMQJHR7 Minor Decreased metabolism of Itraconazole caused by Indacaterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [70]
Levomilnacipran DMV26S8 Major Decreased metabolism of Itraconazole caused by Levomilnacipran mediated inhibition of CYP450 enzyme. Chronic pain [MG30] [71]
Fidaxomicin DMFP6MV Minor Decreased clearance of Itraconazole due to the transporter inhibition by Fidaxomicin. Clostridium difficile enterocolitis [1A04] [54]
Regorafenib DMHSY1I Moderate Decreased metabolism of Itraconazole caused by Regorafenib mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [54]
Intedanib DMSTA36 Moderate Decreased metabolism of Itraconazole caused by Intedanib mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [72]
Drospirenone DM1A9W3 Major Decreased metabolism of Itraconazole caused by Drospirenone mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [54]
Levonorgestrel DM1DP7T Moderate Decreased metabolism of Itraconazole caused by Levonorgestrel mediated inhibition of CYP450 enzyme. Contraceptive management [QA21] [65]
Osilodrostat DMIJC9X Major Decreased metabolism of Itraconazole caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [51]
Ivacaftor DMZC1HS Major Decreased metabolism of Itraconazole caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [54]
Rivaroxaban DMQMBZ1 Major Decreased clearance of Itraconazole due to the transporter inhibition by Rivaroxaban. Deep vein thrombosis [BD71] [54]
Escitalopram DMFK9HG Minor Decreased metabolism of Itraconazole caused by Escitalopram mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [73]
OPC-34712 DMHG57U Major Decreased metabolism of Itraconazole caused by OPC-34712 mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [74]
Clomipramine DMINRKW Moderate Decreased metabolism of Itraconazole caused by Clomipramine mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [58]
Polatuzumab vedotin DMF6Y0L Major Decreased metabolism of Itraconazole caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [75]
[3H]estrone-3-sulphate DMGPF0N Moderate Decreased metabolism of Itraconazole caused by [3H]estrone-3-sulphate mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [76]
Ospemifene DMC4GEI Moderate Decreased metabolism of Itraconazole caused by Ospemifene mediated inhibition of CYP450 enzyme. Dyspareunia [GA12] [77]
Ingrezza DMVPLNC Major Additive CNS depression effects by the combination of Itraconazole and Ingrezza. Dystonic disorder [8A02] [78]
Cenobamate DMGOVHA Moderate Increased metabolism of Itraconazole caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [79]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Itraconazole caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [54]
Lacosamide DMVM6QR Moderate Decreased metabolism of Itraconazole caused by Lacosamide mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [54]
Rufinamide DMWE60C Moderate Increased metabolism of Itraconazole caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [51]
Phenobarbital DMXZOCG Moderate Increased metabolism of Itraconazole caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [54]
Cannabidiol DM0659E Minor Decreased metabolism of Itraconazole caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [51]
Bay 80-6946 DMLOS5R Major Decreased metabolism of Itraconazole caused by Bay 80-6946 mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [80]
Tazemetostat DMWP1BH Major Decreased metabolism of Itraconazole caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [81]
Solifenacin DMG592Q Major Decreased metabolism of Itraconazole caused by Solifenacin mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [54]
Mirabegron DMS1GYT Minor Decreased metabolism of Itraconazole caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [82]
Dexlansoprazole DM1DBV5 Moderate Decreased absorption of Itraconazole due to altered gastric pH caused by Dexlansoprazole. Gastro-oesophageal reflux disease [DA22] [83]
Ripretinib DM958QB Major Decreased metabolism of Itraconazole caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [54]
Sunitinib DMCBJSR Moderate Decreased metabolism of Itraconazole caused by Sunitinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [54]
Avapritinib DMK2GZX Major Decreased metabolism of Itraconazole caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [51]
Colchicine DM2POTE Major Decreased metabolism of Itraconazole caused by Colchicine mediated inhibition of CYP450 enzyme. Gout [FA25] [84]
Boceprevir DMBSHMF Moderate Decreased metabolism of Itraconazole caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [85]
Simeprevir DMLUA9D Major Decreased metabolism of Itraconazole caused by Simeprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [54]
Telaprevir DMMRV29 Moderate Decreased metabolism of Itraconazole caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [85]
Daclatasvir DMSFK9V Major Decreased metabolism of Itraconazole caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [51]
Rifapentine DMCHV4I Major Increased metabolism of Itraconazole caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [86]
Brentuximab vedotin DMWLC57 Moderate Decreased clearance of Itraconazole due to the transporter inhibition by Brentuximab vedotin. Hodgkin lymphoma [2B30] [87]
MK-1439 DM215WE Minor Decreased metabolism of Itraconazole caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [88]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Itraconazole caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [89]
Fostemsavir DM50ILT Moderate Decreased clearance of Itraconazole due to the transporter inhibition by Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [90]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Itraconazole caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [91]
Dolutegravir DMCZGRE Minor Decreased metabolism of Itraconazole caused by Dolutegravir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [92]
Saquinavir DMG814N Moderate Decreased metabolism of Itraconazole caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [58]
Rilpivirine DMJ0QOW Moderate Increased metabolism of Itraconazole caused by Rilpivirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [93]
Darunavir DMN3GCH Moderate Decreased metabolism of Itraconazole caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [54]
Maraviroc DMTL94F Major Decreased metabolism of Itraconazole caused by Maraviroc mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [94]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Itraconazole and Mipomersen. Hyper-lipoproteinaemia [5C80] [95]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Itraconazole and Teriflunomide. Hyper-lipoproteinaemia [5C80] [96]
BMS-201038 DMQTAGO Major Decreased metabolism of Itraconazole caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [54]
Sodium zirconium cyclosilicate DMCSLZ4 Moderate Decreased absorption of Itraconazole due to altered gastric pH caused by Sodium zirconium cyclosilicate. Hyperkalaemia [5C76] [51]
Aliskiren DM1BV7W Major Decreased clearance of Itraconazole due to the transporter inhibition by Aliskiren. Hypertension [BA00-BA04] [54]
Tolvaptan DMIWFRL Major Decreased metabolism of Itraconazole caused by Tolvaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [54]
Retapamulin DM9JXB7 Minor Decreased metabolism of Itraconazole caused by Retapamulin mediated inhibition of CYP450 enzyme. Impetigo [1B72] [97]
TP-434 DM5A31S Minor Decreased metabolism of Itraconazole caused by TP-434 mediated inhibition of CYP450 enzyme. Infectious gastroenteritis/colitis [1A40] [98]
Berotralstat DMWA2DZ Major Decreased clearance of Itraconazole due to the transporter inhibition by Berotralstat. Innate/adaptive immunodeficiency [4A00] [99]
Suvorexant DM0E6S3 Major Decreased metabolism of Itraconazole caused by Suvorexant mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [54]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Itraconazole caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [100]
ITI-007 DMUQ1DO Major Decreased metabolism of Itraconazole caused by ITI-007 mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [101]
Eluxadoline DMYZ0P1 Moderate Decreased metabolism of Itraconazole caused by Eluxadoline mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [102]
Naloxegol DML0B41 Major Decreased metabolism of Itraconazole caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [54]
Pemigatinib DM819JF Major Decreased metabolism of Itraconazole caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [51]
Crizotinib DM4F29C Major Decreased metabolism of Itraconazole caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [54]
Brigatinib DM7W94S Major Decreased metabolism of Itraconazole caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [103]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Itraconazole caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [104]
PF-06463922 DMKM7EW Major Decreased metabolism of Itraconazole caused by PF-06463922 mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [105]
Osimertinib DMRJLAT Major Decreased metabolism of Itraconazole caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [106]
Pralsetinib DMWU0I2 Major Decreased clearance of Itraconazole due to the transporter inhibition by Pralsetinib. Lung cancer [2C25] [107]
Capmatinib DMYCXKL Major Decreased metabolism of Itraconazole caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [108]
Selpercatinib DMZR15V Major Decreased metabolism of Itraconazole caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [51]
Halofantrine DMOMK1V Major Decreased metabolism of Itraconazole caused by Halofantrine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [109]
Hydroxychloroquine DMSIVND Moderate Decreased metabolism of Itraconazole caused by Hydroxychloroquine mediated inhibition of CYP450 enzyme. Malaria [1F40-1F45] [54]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Itraconazole and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [110]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Itraconazole and Idelalisib. Mature B-cell leukaemia [2A82] [111]
GDC-0199 DMH0QKA Major Decreased metabolism of Itraconazole caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [112]
Acalabrutinib DM7GCVW Major Decreased metabolism of Itraconazole caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [113]
Ibrutinib DMHZCPO Major Decreased metabolism of Itraconazole caused by Ibrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [54]
Ponatinib DMYGJQO Major Decreased metabolism of Itraconazole caused by Ponatinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [54]
Arry-162 DM1P6FR Moderate Decreased clearance of Itraconazole due to the transporter inhibition by Arry-162. Melanoma [2C30] [54]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Itraconazole caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [114]
Selumetinib DMC7W6R Major Decreased metabolism of Itraconazole caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [115]
Ubrogepant DM749I3 Major Decreased metabolism of Itraconazole caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [116]
Rimegepant DMHOAUG Moderate Decreased metabolism of Itraconazole caused by Rimegepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [117]
Exjade DMHPRWG Moderate Decreased metabolism of Itraconazole caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [118]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Itraconazole due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [96]
Flibanserin DM70DTN Major Decreased metabolism of Itraconazole caused by Flibanserin mediated inhibition of CYP450 enzyme. Mood disorder [6A60-6E23] [119]
Panobinostat DM58WKG Major Decreased metabolism of Itraconazole caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [120]
Siponimod DM2R86O Major Decreased metabolism of Itraconazole caused by Siponimod mediated inhibition of CYP450 enzyme. Multiple sclerosis [8A40] [54]
Deflazacort DMV0RNS Major Decreased metabolism of Itraconazole caused by Deflazacort mediated inhibition of CYP450 enzyme. Muscular dystrophy [8C70] [51]
Romidepsin DMT5GNL Moderate Decreased metabolism of Itraconazole caused by Romidepsin mediated inhibition of CYP450 enzyme. Mycosis fungoides [2B01] [121]
Fedratinib DM4ZBK6 Major Decreased metabolism of Itraconazole caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [51]
Nilotinib DM7HXWT Major Decreased metabolism of Itraconazole caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [54]
Ruxolitinib DM7Q98D Major Decreased metabolism of Itraconazole caused by Ruxolitinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [122]
Dasatinib DMJV2EK Major Decreased metabolism of Itraconazole caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [54]
Vorapaxar DMA16BR Major Decreased metabolism of Itraconazole caused by Vorapaxar mediated inhibition of CYP450 enzyme. Myocardial infarction [BA41-BA43] [54]
E-2007 DMJDYNQ Minor Decreased metabolism of Itraconazole caused by E-2007 mediated inhibition of CYP450 enzyme. Neuropathy [8C0Z] [51]
Levomethadyl Acetate DM06HG5 Major Decreased metabolism of Itraconazole caused by Levomethadyl Acetate mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [123]
S-297995 DM26IH8 Moderate Decreased metabolism of Itraconazole caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [51]
Olaparib DM8QB1D Major Decreased metabolism of Itraconazole caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [54]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Itraconazole caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [124]
MK-4827 DMLYGH4 Moderate Decreased clearance of Itraconazole due to the transporter inhibition by MK-4827. Ovarian cancer [2C73] [125]
Istradefylline DM20VSK Major Decreased metabolism of Itraconazole caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [126]
Pimavanserin DMR7IVC Major Decreased metabolism of Itraconazole caused by Pimavanserin mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [127]
Bromocriptine DMVE3TK Moderate Decreased metabolism of Itraconazole caused by Bromocriptine mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [58]
Abametapir DM2RX0I Moderate Decreased metabolism of Itraconazole caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [128]
Lefamulin DME6G97 Major Decreased metabolism of Itraconazole caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [129]
Ergonovine DM0VEC1 Major Decreased metabolism of Itraconazole caused by Ergonovine mediated inhibition of CYP450 enzyme. Postpartum haemorrhage [JA43] [130]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Itraconazole caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [131]
ABIRATERONE DM8V75C Minor Decreased metabolism of Itraconazole caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [132]
Enzalutamide DMGL19D Moderate Increased metabolism of Itraconazole caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [133]
Relugolix DMK7IWL Major Decreased clearance of Itraconazole due to the transporter inhibition by Relugolix. Prostate cancer [2C82] [134]
Darolutamide DMV7YFT Moderate Decreased clearance of Itraconazole due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [135]
Silodosin DMJSBT6 Major Decreased metabolism of Itraconazole caused by Silodosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [54]
Finasteride DMWV3TZ Moderate Decreased metabolism of Itraconazole caused by Finasteride mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [58]
Ambrisentan DMD1QXW Minor Decreased metabolism of Itraconazole caused by Ambrisentan mediated inhibition of CYP450 enzyme. Pulmonary hypertension [BB01] [136]
Riociguat DMXBLMP Major Decreased clearance of Itraconazole due to the transporter inhibition by Riociguat. Pulmonary hypertension [BB01] [54]
Axitinib DMGVH6N Major Decreased metabolism of Itraconazole caused by Axitinib mediated inhibition of CYP450 enzyme. Renal cell carcinoma [2C90] [54]
Temsirolimus DMS104F Major Increased metabolism of Itraconazole caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [54]
Ciclesonide DM2NA4K Moderate Decreased metabolism of Itraconazole caused by Ciclesonide mediated inhibition of CYP450 enzyme. Respiratory system disease [CB40-CB7Z] [137]
Upadacitinib DM32B5U Major Decreased metabolism of Itraconazole caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [138]
Dexamethasone DMMWZET Moderate Decreased metabolism of Itraconazole caused by Dexamethasone mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [137]
Quetiapine DM1N62C Major Decreased metabolism of Itraconazole caused by Quetiapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [139]
Aripiprazole DM3NUMH Moderate Decreased metabolism of Itraconazole caused by Aripiprazole mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [140]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Itraconazole and Amisulpride. Schizophrenia [6A20] [54]
Avanafil DM75CXN Major Decreased metabolism of Itraconazole caused by Avanafil mediated inhibition of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [54]
Voxelotor DMCS6M5 Major Decreased metabolism of Itraconazole caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [141]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Itraconazole caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [51]
Larotrectinib DM26CQR Major Decreased metabolism of Itraconazole caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [54]
Ifosfamide DMCT3I8 Moderate Decreased metabolism of Itraconazole caused by Ifosfamide mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [58]
Docetaxel DMDI269 Major Decreased clearance of Itraconazole due to the transporter inhibition by Docetaxel. Solid tumour/cancer [2A00-2F9Z] [142]
Trabectedin DMG3Y89 Major Decreased metabolism of Itraconazole caused by Trabectedin mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [54]
Armodafinil DMGB035 Minor Decreased metabolism of Itraconazole caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [54]
LEE011 DMMX75K Major Decreased metabolism of Itraconazole caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [51]
Vandetanib DMRICNP Minor Decreased metabolism of Itraconazole caused by Vandetanib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [143]
Taxol DMUOT9V Moderate Decreased metabolism of Itraconazole caused by Taxol mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [144]
Pitolisant DM8RFNJ Moderate Increased metabolism of Itraconazole caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [51]
Pomalidomide DMTGBAX Moderate Decreased metabolism of Itraconazole caused by Pomalidomide mediated inhibition of CYP450 enzyme. Systemic sclerosis [4A42] [54]
Fostamatinib DM6AUHV Major Decreased metabolism of Itraconazole caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [145]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Itraconazole due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [124]
As-1670542 DMV05SW Moderate Decreased metabolism of Itraconazole caused by As-1670542 mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [51]
Apixaban DM89JLN Major Decreased clearance of Itraconazole due to the transporter inhibition by Apixaban. Thrombosis [DB61-GB90] [54]
Brilinta DMBR01X Major Decreased metabolism of Itraconazole caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [54]
Cabozantinib DMIYDT4 Major Decreased metabolism of Itraconazole caused by Cabozantinib mediated inhibition of CYP450 enzyme. Thyroid cancer [2D10] [54]
Saxagliptin DMGXENV Moderate Decreased metabolism of Itraconazole caused by Saxagliptin mediated inhibition of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [51]
Elagolix DMB2C0E Major Decreased metabolism of Itraconazole caused by Elagolix mediated inhibition of CYP450 enzyme. Uterine fibroid [2E86] [146]
Fluticasone DMGCSVF Major Decreased metabolism of Itraconazole caused by Fluticasone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [147]
Propafenone DMPIBJK Moderate Decreased metabolism of Itraconazole caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [148]
⏷ Show the Full List of 180 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 22 E00206 11048 Colorant
D&C red no. 28 E00491 6097185 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol E00011 263 Flavoring agent; Solvent
Crospovidone E00626 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
FD&C red no. 3 E00629 Not Available Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Magnesium stearate E00208 11177 lubricant
Poloxamer 188 E00645 Not Available Emulsifying agent; Solubilizing agent; Surfactant
Polyethylene glycol 20000 E00650 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Potassium hydroxide E00233 14797 Alkalizing agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium hydroxide E00234 14798 Alkalizing agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 26 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Itraconazole 100 mg capsule 100 mg Oral Capsule Oral
Itraconazole 200 mg tablet 200 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 076104.
2 BDDCS applied to over 900 drugs
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
10 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
11 Effects of itraconazole and tandospirone on the pharmacokinetics of perospirone. Ther Drug Monit. 2006 Feb;28(1):73-5.
12 Investigation into UDP-glucuronosyltransferase (UGT) enzyme kinetics of imidazole- and triazole-containing antifungal drugs in human liver microsomes and recombinant UGT enzymes. Drug Metab Dispos. 2010 Jun;38(6):923-9.
13 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
14 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
15 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
16 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
17 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
18 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
19 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
20 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
21 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
22 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
23 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
24 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
25 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
26 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
27 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
28 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
29 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
30 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
31 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
32 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
33 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
34 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
35 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
36 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
37 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
38 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
39 A new, broad-spectrum azole antifungal: posaconazole--mechanisms of action and resistance, spectrum of activity. Mycoses. 2006;49 Suppl 1:2-6.
40 Clinical pharmacokinetics and pharmacodynamics of solifenacin. Clin Pharmacokinet. 2009;48(5):281-302.
41 Antifungal agents: mechanisms of action. Trends Microbiol. 2003 Jun;11(6):272-9.
42 Mode of action of anti-Candida drugs: focus on terconazole and other ergosterol biosynthesis inhibitors. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1193-9.
43 Investigation of the role of cytochrome P450 2B4 active site residues in substrate metabolism based on crystal structures of the ligand-bound enzyme. Arch Biochem Biophys. 2006 Nov 1;455(1):61-7.
44 Biological spectra analysis: Linking biological activity profiles to molecular structure. Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):261-6.
45 Differential azole antifungal efficacies contrasted using a Saccharomyces cerevisiae strain humanized for sterol 14 alpha-demethylase at the homolo... Antimicrob Agents Chemother. 2008 Oct;52(10):3597-603.
46 Brass C, Galgiani JN, Blaschke TF, et al "Disposition of ketoconazole, an oral antifungal, in humans." Antimicrob Agents Chemother 21 (1982): 151-8. [PMID: 6282204]
47 Product Information. Cleocin (clindamycin). Pharmacia and Upjohn, Kalamazoo, MI.
48 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
49 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
50 Multum Information Services, Inc. Expert Review Panel.
51 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
52 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
53 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
54 Cerner Multum, Inc. "Australian Product Information.".
55 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
56 Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
57 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
58 Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44. [PMID: 10600094]
59 Product Information. Vraylar (cariprazine). Actavis Pharma, Inc., Parsippany, NJ.
60 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
61 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
62 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
63 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
64 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
65 Devenport MH, Crook D, Wynn V, Lees LJ "Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives." Br J Clin Pharmacol 27 (1989): 851-9. [PMID: 2547410]
66 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
67 Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
68 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
69 Product Information. Breo Ellipta (fluticasone-vilanterol). GlaxoSmithKline, Research Triangle Park, NC.
70 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
71 Product Information. Fetzima (levomilnacipran). Forest Pharmaceuticals, St. Louis, MO.
72 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
73 Product Information. Celexa (citalopram). Forest Pharmaceuticals, St. Louis, MO.
74 Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
75 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
76 Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33. [PMID: 2330488]
77 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
78 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
79 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
80 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
81 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
82 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
83 Bottiger Y, Tybring G, Gotharson E, Bertilsson L "Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin." Clin Pharmacol Ther 62 (1997): 384-91. [PMID: 9357389]
84 Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7. [PMID: 17048210]
85 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
86 Abadie-Kemmerly S, Pankey GA, Dalvisio JR "Failure of ketoconazole treatment of blastomyces dermatidis due to interaction of isoniazid and rifampin." Ann Intern Med 109 (1988): 844-5. [PMID: 3190036]
87 Product Information. VFEND (voriconazole). Pfizer U.S. Pharmaceuticals, New York, NY.
88 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
89 Polk RE, Crouch MA, Israel DS, et al. "Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men." Pharmacotherapy 19 (1999): 1378-84. [PMID: 10600086]
90 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
91 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
92 Product Information. Tivicay (dolutegravir). ViiV Healthcare, Research Triangle Park, NC.
93 Product Information. Edurant (rilpivirine). Tibotec Pharmaceuticals, Titusville, NJ.
94 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
95 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
96 Canadian Pharmacists Association.
97 Product Information. Altabax (retapamulin topical). GlaxoSmithKline, Research Triangle Park, NC.
98 Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
99 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
100 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
101 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
102 Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
103 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
104 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
105 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
106 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
107 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
108 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
109 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
110 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
111 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
112 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
113 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
114 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
115 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
116 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
117 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
118 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
119 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
120 Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13. [PMID: 21706316]
121 Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
122 Product Information. Jakafi (ruxolitinib). Incyte Corporation, Wilmington, DE.
123 Product Information. Orlaam (levomethadyl acetate) Roxanne Laboratories Inc, Columbus, OH.
124 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
125 Product Information. Zejula (niraparib). Tesaro Inc., Waltham, MA.
126 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
127 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
128 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
129 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
130 Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D "Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir." Postgrad Med J 75 (1999): 546-7. [PMID: 10616689]
131 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
132 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
133 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
134 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
135 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
136 Product Information. Letairis (ambrisentan). Gilead Sciences, Foster City, CA.
137 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
138 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
139 DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22. [PMID: 11510628]
140 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
141 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
142 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
143 Martin P, Oliver S, Robertson J, Kennedy SJ, Read J, Duvauchelle T "Pharmacokinetic drug interactions with vandetanib during cadministration with rifampicin or itraconazole." Drugs R D 11 (2011): 37-51. [PMID: 21410294]
144 Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):. [PMID: 26446447]
145 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
146 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
147 Arrington-Sanders R, Hutton N, Siberry GK "Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents." Pediatr Infect Dis J 25 (2006): 1044-1048. [PMID: 17072128]
148 Product Information. Rythmol SR (propafenone). GlaxoSmithKline, Research Triangle Park, NC.